A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- Genome Company Licenses Its First Drug – Thanks to Your DNAon January 10, 2020 at 6:05 am
Now the human genome research company has tapped the sprawling set of medical data it harvested as a result, to successfully licensed its first drug compound; selling rights to the anti-inflammatory ...
- 23andMe signs deal with drug firm to make treatments for psoriasis, lupus and Crohn's out of an antibody it created using its customers' DNAon January 10, 2020 at 2:00 am
DNA testing firm 23andMe has handed over the licence to an antibody it has created using customers' genetic data to develop drugs for skin conditions. Spanish drugmaker Almirall has bought the rights ...
- Flora Enters Into Agreement to Acquire Colombian Pharmaceutical Company, Cronomedon January 9, 2020 at 4:32 pm
Flora Growth Corp. (“Flora” or the “Company”) is pleased to announce that it has entered into a letter of intent (“LOI”) with Latin Canada Pharma Inc. (the “Vendor”) to acquire a 100% equity interest ...
- Global Veterinary Drugs Market 2020 |Market by Product Type Segmentation, Industry Segmentation, Product Type Detail, Downstream Consumeron January 9, 2020 at 8:22 am
Veterinary Drugs Market Industry 2020 Global Market Research report presents an in-depth analysis of the Veterinary Drugs Market size, growth, share, segments, manufacturers, and technologies, key ...
- In search of an anti-inflammatory drug for Alzheimer diseaseon January 9, 2020 at 2:41 am
Evidence suggests that chronic neuroinflammation has an important role in the pathogenesis of Alzheimer disease. However, in a new clinical trial, the tetracycline antibiotic minocycline, which has ...
- Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical studyon January 9, 2020 at 2:22 am
The antilipidemic drug, probucol (PB), has demonstrated potential applications in Type 2 diabetes ... and their hypoglycemic and antilipidemic and anti-inflammatory effects in vivo. PBUDCA and UDCA ...
- Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs Marketon January 9, 2020 at 1:00 am
Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029 Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs LONDON, Jan.
- Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™on January 7, 2020 at 6:05 am
DOYLESTOWN, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company ...
- Sudafed Sinus + Anti-inflammatory Pain Relief Capletson January 6, 2020 at 1:50 pm
Ibuprofen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Ask your pharmacist or doctor if you have any questions about this medicine. Your pharmacist or doctor ...
via Bing News